Navigation Links
FDA Approves First Combo Drug for Diabetes, Cholesterol
Date:10/7/2011

FRIDAY, Oct. 7 (HealthDay News) -- A first-of-a-kind pill that treats both type 2 diabetes and high cholesterol was approved by the U.S. Food and Drug Administration on Friday.

Juvisync is a prescription medication that contains two previously approved medicines, sitagliptin (Januvia) and simvastatin (Zocor). Sitagliptin helps lower blood sugar levels, and simvastatin reduces the amount of "bad" low-density lipoprotein in the blood.

Many of the estimated 20 million people in the United States with type 2 diabetes also have high cholesterol, the FDA researchers noted. The two conditions are associated with increased risk of chronic conditions, such as heart disease, stroke, kidney disease and blindness.

"This is the first product to combine a type 2 diabetes drug with a cholesterol-lowering drug in one tablet," Dr. Mary H. Parks, director of the division of metabolism and endocrinology products in the FDA's Center for Drug Evaluation and Research, said in the news release.

One expert said the two-in-one pill might be of help to some patients.

"Certainly, as 20 million people are suffering with diabetes in this country, aggressive proactive prevention is critical," noted Dr. Suzanne Steinbaum, a preventive cardiologist at Lenox Hill Hospital in New York City. "Perhaps this is the first medication which can help successfully address these significant and pervasive risk factors."

The Juvisync dosage strengths approved by the FDA are 100 milligrams (mg) of sitagliptin with 10 mg, 20 mg or 40 mg of simvastatin. The drug maker -- MSD International GmbH Clonmel, Co. of Ireland -- has promised to develop Juvisync doses with 50 mg/10 mg, 50 mg/20 mg, and 50 mg/40 mg of sitagliptin/simvastatin, according to an FDA news release.

Patients who require a 50-mg dose of sitagliptin should continue to use single-ingredient sitagliptin tablets with that dose until Juvisync with 50 mg of sitagliptin is available, the FDA said.

"To ensure safe and effective use of this product, tablets containing different doses of sitagliptin and simvastatin in fixed-dose combination have been developed to meet the different needs of individual patients. Dose selection should factor in what other drugs the patient is taking," Parks added.

The most common side effects of Juvisync include: upper respiratory infection; stuffy or runny nose and sore throat; headache, muscle and stomach pain; constipation; and nausea.

More information

The U.S. Agency for Healthcare Research and Quality has more about medicines for type 2 diabetes.

-- Robert Preidt

SOURCE: Suzanne Steinbaum, MD, preventive cardiologist, Lenox Hill Hospital, New York City; U.S. Food and Drug Administration, news release, Oct. 7, 2011


'/>"/>
Copyright©2010 ScoutNews,LLC.
All rights reserved  

Related medicine news :

1. Kaiser Permanente Approves $170 Million in Community Benefit Grants in 2009
2. The American Association of Anatomists approves guidelines for body donation programs
3. Golden Meditech Shareholders Approves of Name Change
4. New Jersey Approves Initiative to Expand the Number of Wound Care Certified Professionals
5. Congress Approves Bill Curbing Internet Tobacco Sales in Victory for Kids and Taxpayers
6. House of Representatives Approves Health-Care Reform Bill
7. New York State Office of Mental Health Approves New High Performance Polycarbonate Sheet for Use in All Facilities
8. FDA Approves Stemedica IND for Ischemic Stroke Clinical Trial
9. FDA approves first human neural stem cell clinical trial to treat brain tumors
10. Early detection of cancer: The FDA approves procedure discovered by EPFL researchers
11. FDA approves Merz Pharmaceuticals Xeomin (incobotulinumtoxinA) for the treatment of cervical dystonia and blepharospasm
Post Your Comments:
*Name:
*Comment:
*Email:
Related Image:
FDA Approves First Combo Drug for Diabetes, Cholesterol
(Date:5/26/2016)... , ... May 26, 2016 , ... ... clinical outcomes, hosted members and suppliers for its inaugural Member Conference at the ... their mission of elevating the operational health of America’s healthcare providers. , The ...
(Date:5/26/2016)... ... May 26, 2016 , ... Connor Sports, through ... a partner for the Tamika Catchings Legacy Tour that will commemorate the ... in hardwood basketball surfaces in all forms and levels of the game, Connor Sports ...
(Date:5/26/2016)... ... ... The Woodlands at John Knox Village , Florida’s first Life Plan ... and healing, celebrated its grand opening, today. The Woodlands at John Knox Village is ... Staff. , “This is an incredibly fulfilling time for John Knox Village as we ...
(Date:5/26/2016)... ... ... There are nearly 14.5 million people living with and beyond cancer in the ... 2016, communities around the world will gather to recognize these cancer survivors as part ... is an annual worldwide Celebration of Life that is held on the first Sunday ...
(Date:5/26/2016)... ... 2016 , ... Catalent Pharma Solutions, the leading global provider ... global clinical supply services, today announced two key appointments and the opening of ... strategic growth plans in the Asia Pacific region. , Howard Kim has joined ...
Breaking Medicine News(10 mins):
(Date:5/25/2016)... -- FDA 510(k) clearance covers Confocal ... urological and surgical applications Mauna Kea ... the multidisciplinary confocal laser endomicroscopy (CLE) platform, today ... with the 12 th 510(k) clearance from ... new FDA clearance covers Confocal Miniprobes indicated for ...
(Date:5/25/2016)... , May 25, 2016  According to Kalorama Information, ... billion in 2015.  Though these are challenging times ... opportunity for success for companies that remain optimistic ... of new growth prospects medical device companies spend ... and development (R&D) than do companies in other ...
(Date:5/25/2016)... PARIS , May 25, 2016 ... system disorders, announces that an oral presentation entitled "High doses ... the MS-SPI trial" will be given by Professor Ayman ... the 2nd Congress of the European Academy of Neurology (EAN) ... "MS and related disorders 3" will take place on Sunday, ...
Breaking Medicine Technology: